Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM-IV-TR Schizophrenia

NCT01307800 is registered in ClinicalTrials.gov with Denovo Biopharma LLC as lead sponsor.

NCT NCT01307800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01307800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM-IV-TR Schizophrenia
Lead sponsor
Denovo Biopharma LLC
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2011
Completion date
September 30, 2012
Enrollment
567 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia